Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0Z4QV
|
||||
| Former ID |
DIB011916
|
||||
| Drug Name |
DUP-734
|
||||
| Synonyms |
1-(Cyclopropylmethyl)-4-[2-(4-fluorophenyl)-2-oxoethyl]piperidine hydrobromide
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Psychotic disorders [ICD9: 290-299; ICD10:F20-F29] | Discontinued in Phase 1 | [544981] | ||
| Formula |
C17H23BrFNO
|
||||
| Canonical SMILES |
Fc1ccc(cc1)C(=O)CC2CCN(CC3CC3)CC2
|
||||
| InChI |
1S/C17H22FNO/c18-16-5-3-15(4-6-16)17(20)11-13-7-9-19(10-8-13)12-14-1-2-14/h3-6,13-14H,1-2,7-12H2
|
||||
| InChIKey |
KWRMWQDKOGFMKP-UHFFFAOYSA-N
|
||||
| CAS Number |
CAS 135135-87-4
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | 5-hydroxytryptamine 2A receptor | Target Info | Modulator | ||
| Sigma(1)-type opioid receptor | Target Info | Modulator | |||
| PANTHER Pathway | 5HT2 type receptor mediated signaling pathway | ||||
| WikiPathways | Serotonin Receptor 2 and STAT3 Signaling | ||||
| Serotonin Receptor 2 and ELK-SRF/GATA4 signaling | |||||
| SIDS Susceptibility Pathways | |||||
| Monoamine GPCRs | |||||
| GPCRs, Class A Rhodopsin-like | |||||
| Gastrin-CREB signalling pathway via PKC and MAPK | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| GPCRs, OtherWP2006:miR-targeted genes in squamous cell - TarBase | |||||
| miR-targeted genes in lymphocytes - TarBase | |||||
| References | |||||